AstraZeneca PLC (AZN) Stock Price & Analysis
Market: NASDAQ • Sector: Healthcare • Industry: Drug Manufacturers - General
AstraZeneca PLC (AZN) Profile & Business Summary
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; Lunit for developing AI-Powered Digital Pathology Risk Assessment Tools for NSCLC; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Key Information
| Ticker | AZN |
|---|---|
| Exchange | NASDAQ |
| Official Site | https://www.astrazeneca.com |
Market Trend Overview for AZN
One model, two time views: what the market looks like right now, and where the larger trend is heading over time.
SRE (WhaleQuant Structural Regime Engine) SRE evaluates how price structure evolves across daily and weekly timeframes to define the prevailing market regime. Beyond identifying trends, consolidations, and exhaustion phases, it distinguishes between raw structural strength and deployable participation quality. The model dynamically adjusts for structural context and extension risk, assessing whether conditions are supportive, stretched, fragile, or structurally impaired. Its purpose is not to forecast precise price levels, but to determine whether risk deployment is aligned with underlying market structure.
Longer-Term Market Trend (Mid to Long Term)
Shows the bigger market trend, how strong it is, and where risks may start to build over the next few weeks or months. — Updated as of 2026-07-14 (ET)
As of 2026-07-14, AZN is showing signs of slowing down. Over the longer term, the trend remains bullish.
AZN last closed at 164.50. The price is about 3.8 ATR below its recent average price (182.36), and the market is currently in a trend that may be losing strength. Price at 164.50 is near minor support around 156.17. Momentum may slow, while minor resistance sits near 180.44. View Support & Resistance from Options
Short-term weakness is unfolding within a broader uptrend, suggesting a pullback rather than a full trend reversal.
Trend score: 55 out of 100. Overall alignment is unclear. The market is currently in a late-stage trend that may be losing strength. The longer-term trend is still positive, but short-term signals are not yet confirming it.
Price is stretched well below its recent average (about 3.8 ATR). Downside extension is elevated, and chasing weakness here carries a higher rebound risk.
There is no clear key risk boundary right now.
On 2026-07-09, trend conditions deteriorated, suggesting that moves in the prior direction became less dependable.
[2026-06-18] Price moved quickly and looked strong, but participation was limited.
Recent price action continues to trend lower in a relatively orderly manner, with no clear signs of structural stabilization yet emerging.
Some late-day positioning was observed, but it lacked strong overnight commitment.
The model still sees a directional lean, but the edge is not thick enough after adjusting for reward/risk.
The model does not deploy this setup because the directional lean exists, but the edge is still not thick enough after risk adjustment, reward/risk remains too thin at -0.11 after adjustment, the setup already looks stretched, recent price behavior has shown failed reversal memory, and there is meaningful next-session pullback or digestion risk. Predictability is 49%, agreement is 93%, and reversal risk is 34%.
NOTE: This next-day up/down probability forecast module is still being tested for accuracy. Please do not rely on it for investment decisions. The model does not account for black swan events or company-specific fundamental news, and its estimates are based solely on technical conditions, capital flow, and market sentiment. View forecast history
This reading is based on the last 20 trading days of 15-minute price, volume, and VWAP data. Price is trading 7.9% below the recent estimated cost basis of 178.62, so the recent structure is still leaning under pressure. Price is below the main cost band (168.59 to 170.21), and roughly 100% of recent positioning remains under water. That means rebounds can still run into supply from trapped holders. The broader structure still looks stretched on the weak side, so recovery attempts may need more proof before improving the tone. The higher up selling area sits around 165.64 to 166.44, so rebounds may begin to slow as price pushes into that zone. The main cost band is fairly wide relative to recent ATR, so this structure may behave less cleanly than a tighter setup. From a trading point of view, this setup remains tougher until price can reclaim the lower edge of the main cost band near 168.59.